Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme
Chin Hang Yiu, Bella D Ianni, Richard O Day, Jacques Raubenheimer, Christine Y Lu · 2026
Read Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme by Chin Hang Yiu, Bella D Ianni, Richard O Day, Jacques Raubenheimer, Christine Y Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13339297.txt.
Description
Yiu and co-authors count what Australia saved when cheaper biosimilar versions of three blockbuster arthritis drugs joined its national subsidy scheme. Biologic drugs are among the costliest lines in any health budget, and copycat biologics promise relief. Using public scheme data from 2015 to 2025, the team compared actual spending with a modeled world where the biosimilars never arrived, taking the scheme's own price-cut rules into account.
The biosimilars saved an estimated 562 million Australian dollars over the decade. One drug, etanercept, delivered most of the savings, helped by early entry. Adalimumab saved less than its huge use would suggest because its copies arrived late. Most savings came from rheumatoid arthritis care. The authors' lesson travels beyond Australia: in a regulated pricing system, when a biosimilar enters matters as much as how good it is. Timing and price rules together decide the public payoff.
Catalog record
| CREATOR | Chin Hang Yiu, Bella D Ianni, Richard O Day, Jacques Raubenheimer, Christine Y Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |